scholarly journals Differentiation syndrome-induced Myopericarditis in the induction therapy of acute Promyelocytic leukemia: a case report

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Shabari Mangalore Shenoy ◽  
Thomas Di Vitantonio ◽  
Anna Plitt ◽  
Rocio Perez-Johnston ◽  
Jillian Gutierrez ◽  
...  

Abstract Background All trans retinoic acid (ATRA) has revolutionized the treatment and outcomes of patients with Acute Promyelocytic Leukemia (APL). Induction therapy with ATRA is associated with the rare but potentially fatal complication of differentiation syndrome. While the presentation of this syndrome is varied, myopericarditis as a manifestation of differentiation syndrome is often fatal and rarely reported in literature. We present a case of myopericarditis as the sole manifestation of differentiation syndrome in a patient on induction therapy with ATRA and arsenic trioxide for APL. Clinical presentation A 62 year old woman with remote history of breast and uterine cancer presented to the hospital for expedited work up of easy bruising and expanding hematomas. She was diagnosed with APL with peripheral blood and bone marrow cytogenetics revealing t (15;17) translocation and initiated on induction therapy with ATRA and ATO as well as steroids for differentiation syndrome prophylaxis. Eighteen days into induction therapy, patient developed pleuritic chest pain, elevated cardiac biomarkers, ECG changes suggestive of pericarditis. Cardiac magnetic resonance imaging showed patchy multifocal sub-epicardial late gadolinium enhancement and elevated T2 signal consistent with acute myopericarditis. Given the timing of symptom onset and lack of other identifiable cause, patient was diagnosed with differentiation syndrome- induced myopericarditis and promptly initiated on high dose steroids with rapid improvement in symptoms, ECG, and cardiac biomarkers. Patient successfully resumed dose-reduced ATRA and arsenic trioxide without complication. Conclusion Myopericarditis can be the sole manifestation of differentiation syndrome and the presentation may be atypical owing to the use of prophylactic steroids as illustrated in our patient’s case. A high index of suspicion for differentiation syndrome, multimodality imaging, and prompt input from multidisciplinary providers is crucial for making the timely diagnosis and initiating life-saving treatment.

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Pin-Zi Chen ◽  
Yee-Jen Wu ◽  
Chien-Chih Wu ◽  
Yu-Wen Wang

A 41-year-old man with newly diagnosed acute promyelocytic leukemia (APL) received induction chemotherapy, containing all-trans retinoic acid (ATRA), idarubicin, and arsenic trioxide. On the 11th day of therapy, he experienced complete atrioventricular (AV) block; therefore, ATRA and arsenic trioxide were immediately postponed. His heart rate partially recovered, and ATRA was rechallenged with a half dose. However, complete AV block as well as differentiation syndrome recurred on the next day. ATRA was immediately discontinued, and a temporary pacemaker was inserted. Two days after discontinuing ATRA, AV block gradually improved, and ATRA was uneventfully rechallenged again. The Naranjo adverse drug reaction probability scale was 7 for ATRA, suggesting it was the probable cause of arrhythmia. A literature search identified 6 other cases of bradycardia during ATRA therapy, and all of them occurred during APL induction therapy, with onset ranging from 4 days to 25 days. Therefore, monitoring vital signs and performing electrocardiogram are highly recommended during the first month of induction therapy with ATRA. ATRA should be discontinued if complete AV block occurs. Rechallenging with ATRA can be considered in fully recovered and clinically stable patients.


2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 16533-16533
Author(s):  
S. A. Aziz

16533 Acute Promyelocytic Leukemia (APL) is a separate, distinct and biologically unique subset of Acute Myelogenous Leukemia (AML). The affordability of ATRA is detrimental for its use especially in the developing world. The use of Arsenic trioxide (As2O3) has radically changed the treatment, initially for relapsed APL and now is being used upfront as first line therapy in APL some studies. We accrued 11 cases (6 males, 5 females) of APL for the past 1 year. 2 patients of these had been already treated with ATRA + chemotherapy (Daunorubicin and Cytosine Arabanoside). These relapsed patients were switched over to Arsenic trioxide. One of these relapsed patients has completed the treatment and is in CR for the past 6 months after completing treatment. The other patient has recently completed the treatment and is in remission. 9 of our patients are newly diagnosed and could not afford ATRA and chemotherapy. All these patients were explained the treatment protocol and after obtaining a formal consent, patients were put on Arsenic trioxide. The protocol consists of Induction therapy with Arsenic trioxide given in a dose of 0.15 mg/kg/day till CR is achieved or to a maximum of 60 doses, followed by Consolidation treatment with Arsenic trioxide in the similar dose schedule but only for 28 days, and finally Maintenance therapy with Arsenic trioxide every 10 days a month for a total of 6 months with an interval of 4–6 weeks in between the cycles. Of the remaining patients (n = 7), 2 patients did not respond to Arsenic trioxide after 60 doses. The remaining patients (n = 5) are in different phases of treatment (all having completed Induction therapy) and are presently in CR (Mean duration to avhieve CR-57 days, documented by bone marrow examination). There were no major morbidities and none of our patients exhibited APL syndrome. The lower cost of treatment with Arsenic trioxide (Approx. Rs. 50–60,000) compared to ATRA + chemotherapy (Approx. Rs. 90,000–1,10,000), the magnitude of response and the least encountered adverse effects seem awesome in this treatment especially in the developing countries. No significant financial relationships to disclose.


2004 ◽  
Vol 72 (4) ◽  
pp. 280-284 ◽  
Author(s):  
Kenji Ishitsuka ◽  
Akihiko Shirahashi ◽  
Yasuhiro Iwao ◽  
Mikiko Shishime ◽  
Yasushi Takamatsu ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 8 (20) ◽  
pp. 32550-32565 ◽  
Author(s):  
Nélida I. Noguera ◽  
Elvira Pelosi ◽  
Daniela F. Angelini ◽  
Maria Liliana Piredda ◽  
Gisella Guerrera ◽  
...  

2018 ◽  
Vol 66 ◽  
pp. 85-88 ◽  
Author(s):  
Ardeshir Ghavamzadeh ◽  
Mahdi Jalili ◽  
Sharbanoo Rostami ◽  
Marjan Yaghmaie ◽  
Leyla Sharifi Aliabadi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document